Yazar "Sahin, Fahri" seçeneğine göre listele
Listeleniyor 1 - 20 / 117
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe A 54-year-old diabetic man with low serum cholesterol(Federacion Bioquimica Provincia Buenos Aires, 2012) Turk, Ugur; Basol, Gunes; Barutcuoglu, Burcu; Sahin, Fahri; Habif, Sara; Tarugi, Patrizia; Bayindir, OyaÖğe A Single-Center Retrospective Evaluation of The Incidence and Survival of Invasive Fungal Infection in Allogeneic Stem Cell Transplant Patients(Galenos Publishing House, 2024) Osabas, Emre; Gunes, Ajda; Soyer, Nur; Tobu, Mahmut; Sahin, Fahri; Saydam, Guray; Arda, Bilgin; Vural, FilizAim: The incidence of invasive fungal infection (IFI) is high in patients undergoing allogeneic hematopoietic stem cell transplantation. Despite new antifungal agents, IFI is still an important cause of mortality. Our study aimed to determine the risk factors of IFI and its effect on mortality. Materials and Methods: One hundred and fifty-four patients who underwent allogeneic transplantation were included in the study. Demographic characteristics, underlying disease, transplantation characteristics, and IFI status of all patients were evaluated retrospectively. The study group was divided into two: 75 patients with definite, high probability and possible IFI (group 1) and 79 patients without IFI (group 2) according to the criteria of the international committee. Results: Of 154 patients, 92 were male (59.7%) and 62 were female (40.3%) with a mean age of 41.87 +/- 14.04 years (range: 18-67 years). The most common transplant indication was acute myeloid leukemia in 58 patients (37.7%). In the analyzes performed on two groups, more IFI were observed in those who had acute graft-versus-host disease after transplantation (p= 0.035) and in those with CMV reactivation (p=0.002). The mean neutropenia duration was 30.89 +/- 20.40 in group 1 and 19.98 +/- 11.01 in group 2 (p=0.001). Underlying diseases, preparation regimen, donor compatibility, consanguineous marriage and IFI history were not found to be significant in terms of the development of IFI. The mortality rate due to IFI was found to be 24%. The mean duration of neutropenia was found to be longer in patients who died (p=0.02). Conclusion: In our study, the frequency of IFI, risk factors and mortality rates were found to be similar to the literature. It would be appropriate for each center to evaluate the frequency of IFI and the risk factors that increase it and decide which treatment strategy is more beneficial for their patients.Öğe Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees(Wiley, 2024) Vahabi, Arman; Er, Erdem; Bicer, Elcil Kaya; Sahin, Fahri; Kavakli, Kaan; Aydogdu, SemihIntroductionIn total knee arthroplasty (TKA), choosing the correct implant size is important. There is lack of data on accuracy of templating on haemophilic knees. Our aim was to test the accuracy of 2D digital templating for TKA on haemophilic arthropathy (HA) of knee.Materials and MethodsTKAs performed on HA between January 2011 and January 2022 were screened. Osteoarthritis (OA) group was created as control group by a one-to-one matching regarding type of implant used. Intra- and interobserver correlations were measured in HA, then correlation between templated and implanted sizes was investigated in four assessments (femur AP, femur lateral, tibia AP, tibia lateral), then compared with OA group. Fifty-eight knees in each group included.ResultsRegarding intraobserver correlation in HA, there was excellent correlation for femur AP [.93 (.73-.98)], femur lateral [.98 (.91-.99)], and tibia AP (1.0) templating. Regarding interobserver correlation in HA, excellent correlation was observed for femur lateral [.93 (.74-.98)] and tibia AP templating [.90 (.65-.97)]. Regarding correlation of templated and applied sizes in HA; tibia AP, tibia lateral and femur lateral templating showed good correlation [.81 (.70-.89), .86 (.77-.91), .79 (.67-.87) while femur AP templating showed moderate correlation [.67 (.50-.79)]. Comparing HA and OA, there was no difference in correlation levels regarding femur AP, femur lateral, tibia AP and tibia lateral templating (p = .056, p = .781, p = .761, p = .083, respectively).ConclusionAlthough 2D digital templating shows comparable correlation in HA and OA, clinical applicability of templating on HA appears to be limited in its current state.Öğe add(12)(q24) and trisomy 14 acquired during clonal evolution in a patient with atypical myeloproliferative disorder harboring t(8;13)(p12;q12)(Springer, 2007) Sahin, Fahri; Ay, Ertan; Yuksel, Erdinc; Ertan, Yesim; Ocakci, Serkan; Tombuloglu, Murat; Saydam, Güray; Sercan, ZeynepÖğe Adult Onset Langerhans Cell Histiocytosis: A Single Center Experience(Cig Media Group, Lp, 2018) Ozcan, Mehmet Ali; Davulcu, Eren Arslan; Ulusoy, Yusuf; Demir, Derya; Kamer, Serra; Bulbul, Hale; Atilla, Dilan; Soyer, Nur Akad; Sahin, Fahri; Hekimgil, Mine; Saydam, GürayÖğe Allogeneic Heamatopoietic Stem Cell Transplantation in Elderly Patients; Single Centre Experience(Nature Publishing Group, 2018) Bulbul, Hale; Atilla, Fatos Dilan; Soyer, Nur Akad; Tombuloglu, Murat; Tobu, Mahmut; Sahin, Fahri; Vural, Filiz[No Abstract Available]Öğe Allogeneic hematopoietic stem cell transplantation in adult aplastic anaemia patients: Promising treatment modality(Nature Publishing Group, 2019) Davulcu, Eren Arslan; Bulbul, Hale; Ulusoy, Yusuf; Soyer, Nur Akad; Karadag, Fatma Keklik; Arslan, Aysenur; Sahin, Fahri; Tobu, Mahmut; Saydam, Güray; Tombuloglu, Murat; Vural, FilizÖğe Amyloid deposition in knee and ankle joints in the course of multiple myeloma(Elsevier France-Editions Scientifiques Medicales Elsevier, 2007) Sahin, Fahri; Soyer, Nur Akad; Saydam, Güray; Vural, Filiz; Tombuloglu, Murat; Argin, Mehmet; Ertan, YesimÖğe ANALYSIS OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES UNDERGONE STEM CELL TRANSPLANTATION UNDER VORICONAZOLE PROPHYLAXIS(Nature Publishing Group, 2018) Davulcu, Eren Arslan; Soyer, Nur; Tombuloglu, Murat; Tobu, Mahmut; Saydam, Guray; Sahin, Fahri; Vural, Filiz[No Abstract Available]Öğe Bilateral Lacrimal Gland Lymphoma in Sjogren Syndrome(Hindawi Ltd, 2016) Palamar, Melis; Ozsan, Nazan; Sahin, FahriA 31-year-old female with Primary Sjogren Syndrome (pSS) presented with bilateral puffiness around the eye for 3 years. The lacrimal glands were hypertrophic and edematous bilaterally. Schirmer 1 score was 2 and 1 mm and tear-film break-up time was 3 and 4 seconds, in the right and the left eyes, respectively. An incisional biopsy from the left lacrimal gland revealed diffuse and intense CD20, CD5, and bcl-2 positivity with negative cyclin D1 and CD23 which supported lymphoma. Upon haematology consultation extranodal marginal zone lymphoma diagnosis was made. CHOP (cyclophosphamide, doxorubicin, vincristine, and methyl prednisolone) treatment was initiated. In conclusion, pSS is a well known autoimmune disease in which increased rate of lymphoma is present. Early detection with histopathologic confirmation and multidisciplinary approach with ophthalmology, rheumatology, and haematology are mandatory in these patients.Öğe Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells(Springer, 2014) Selvi, Nur; Kaymaz, Burcin Tezcanli; Gunduz, Cumhur; Aktan, Cagdas; Kiper, Hatice Demet; Sahin, Fahri; Comert, Melda; Selvi, Ali Fatih; Kosova, Buket; Saydam, GürayIn the current study, we aimed to identify the cytotoxic and apoptotic effects of bortezomib (BOR) on human K562 chronic myelogenous leukemia cells and to evaluate the potential roles of Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway members STAT3, STAT5, and JAK2 on BOR-induced cell death of leukemic cells. Cell viability was assessed via trypan blue dye exclusion test, and cytotoxicity of the BOR-treated cells was conducted by 2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT) assay. The relative messenger RNA (mRNA) expression levels of STAT3, STAT5A, STAT5B, and JAK2 were analyzed by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). On the other hand, their protein expression levels were detected by western blot method. The obtained results indicated that BOR treatment reduced cell viability and induced leukemic cell apoptosis in a dose- and time-dependent manner as compared to untreated control cells. While mRNA expression levels of STAT5A, STAT5B, and STAT3 were significantly reduced following BOR treatment when compared to untreated controls, it had no effect upon JAK2 mRNA expression. As for protein levels, STAT expressions were downregulated after BOR treatment especially at 72nd and 96th hours. Our results pointed out that BOR treatment had a significant potential of being an anticancer agent for chronic myelogenous leukemia therapy, and this effect could be due to the expressional downregulations of JAK/STAT pathway members.Öğe Caffeic acid phenethyl ester triggers apoptosis through induction of loss of mitochondrial membrane potential in CCRF-CEM cells(Springer, 2011) Avci, Cigir Biray; Gunduz, Cumhur; Baran, Yusuf; Sahin, Fahri; Yilmaz, Sunde; Dogan, Zeynep Ozlem; Saydam, GürayCAPE (caffeic acid phenethyl ester) is one of the most valuable and investigated component of propolis which is composed by honeybees. In the current study, we aimed at examining apoptotic effects of CAPE on CCRF-CEM leukemic cells and at determining the roles of mitochondrial membrane potential (MMP) in cell death. Trypan blue and XTT methods were used to evaluate the cytotoxicity. Apoptosis was examined by ELISA-based oligonucleotide and acridine orange/ethidium bromide dye techniques. Loss of mitochondrial membrane potential was evaluated using JC-1 dye by flow cytometric analysis and under fluorescent microscope. We detected the time- and dose-dependent increases in cytotoxic effect of CAPE on CCRF-CEM cells. ELISA and acridine orange/ethidium bromide results showed that apoptotic cell population increased significantly in CCRF-CEM cells exposed to increasing concentrations of CAPE. On the other hand, there was significant loss of MMP determined in response to CAPE in CCRF-CEM cells. This in vitro data by being supported with clinical data may open the way of the potential use of CAPE for the treatment of leukemia.Öğe Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?(Elsevier Science Bv, 2015) Cetinkalp, Sevki; Simsir, Ilgin Yildirim; Sahin, Fahri; Saydam, Güray; Ural, Ali Ugur; Yilmaz, CandegerPPARs are ligand-regulated transcription factors and regulate expression of several gene products. Therefore, PPARs are being studied for their possible contribution to the treatment of cancer, atherosclerosis, inflammation, infertility and demyelinating diseases. Primary AML patients were observed to have significantly elevated PPAR gamma mRNA expression compared to normal peripheral blood or bone marrow mononuclear cells. This study investigated the cytotoxic effects of rosiglitazone maleate, a pure PPAR gamma agonist, in vitro in HL-60 cell line. This study obtained results which can provide guidance for future studies. Whether the PPARy agonist rosiglitazone maleate may provide additive effects in refractory or relapsing cases of acute leukemia may be set as an objective for the future studies. (C) 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Öğe Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience(Tubitak Scientific & Technical Research Council Turkey, 2018) Uysal, Ayse; Akad Soyer, Nur; Ozkan, Melda; Sahin, Fahri; Vural, Filiz; Tobu, Mahmut; Tombuloglu, Murat; Saydam, GürayBackground/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. The patients were followed until March 2016 after CFZ treatment. Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47-76) years. The median number of prior treatment lines was 3 (2-7). The median number of administered cycles of treatment for CFZ was 4 (1-10). The median overall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7-9) and 3 (2-16) months, respectively. The median overall survival was 8 (0.5-33) months. Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.Öğe Castleman's Disease: The Experience Over 17 Years(Cig Media Group, Lp, 2018) Saydam, Güray; Atilla, Fatos Dilan; Demir, Derya; Bulbul, Hale; Davulcu, Eren Arslan; Ulusoy, Yusuf; Hekimgil, Mine; Ozsan, Nazan; Sahin, FahriÖğe Chronic Hepatitis B Infection Management During Long-Term Follow-Up of Chronic Lymphocytic Leukemia (CLL) Treated With Multiple Lines of Chemoimmunotherapy, Including Ibrutinib(Cig Media Group, Lp, 2023) Sevgili, Bahar; Güneş, Ajda; Soyer, Nur; Sahin, Fahri; Oruc, Nevin; Saydam, Güray[No abstract available]Öğe Clinical Features and Outcomes of Solitary Plasmacytomas: Single-Center Experience from Turkey(Cig Media Group, Lp, 2018) Saydam, Güray; Ulusoy, Yusuf; Davulcu, Eren Arslan; Soyer, Nur; Kamer, Emine Serra; Ozsan, Nazan; Hekimgil, Mine; Sahin, FahriÖğe The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia(Akad Doktorlar Yayinevi, 2012) Aksu, Salih; Sahin, Fahri; Uz, Burak; Yavuz, Selim A.; Atay, Hilmi; Kelkitli, Engin; Turgut, Mehmet; Pehlivan, Mustafa; Akay, Meltem O.; Guray, Emel; Demir, Muzaffer; Kahraman, Selda; Demirkan, Fatih; Paydas, Semra; Saydam, Güray; Haznedaroglu, Ibrahim C.We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.Öğe Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period(Akad Doktorlar Yayinevi, 2014) Vural, Filiz; Karaca, Emin; Soyer, Nur; Gunduz, Cumhur; Sahin, Fahri; Kosova, Buket; Saydam, Güray; Cagirgan, Seckin; Tombuloglu, Murat; Özkınay, Ferda; Cogulu, OzgurChronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults. Recently CD38, ZAP70 and hTERT activity have been studied for the evaluation of the prognosis of CLL besides clinical staging and lymphocyte doubling time. There are inconsistent results regarding these markers for the evaluation of the prognosis in CLL patients. In this study CD38, ZAP70 and hTERT values in CLL patients were measured to make comparisons between each other and known prognostic factors. Thirty CLL patients who were included in the study were followed up for 5 years after the initial diagnosis. The mean hTERT value in CLL and control cases were 1.00 +/- 1.31 and 3.89 +/- 3.58, respectively (p< 0.05). The mean CD38 and ZAP70 were 6.20 +/- 7.60 and 5.51 +/- 5.67, respectively. No significant association was detected between CD38, ZAP70 and hTERT activity. There was no correlation between those parameters and known prognostic parameters such as Rai staging, peripheral lymphocyte levels, age, and sex of the patients, beta-2 microglobulin and reply to treatment in CLL. The overall five-year survival rate in CLL patients is 96.7%. The overall five-year survival rate in CLL patients is 96.7%. In conclusion, further studies including larger series of patients with longer follow-up periods are recommended.Öğe Correlation between HJHS and HEAD-US Scores during Prophylaxis in Turkish Patients with Hemophilia: National Prospective Observational Study(Wiley, 2020) Kavakli, Kaan; Antmen, Bulent; Eyupoglu, S. Selin Aytac; Sahin, Fahri; Zulfikar, Bulent; Sonmez, Mehmet; Bulakci, Mesut[No abstract available]
